2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17572S
    Atosiban-d5 TFA
    Atosiban-d5 TFA (RW22164-d5 TFA) is the deuterium labeled Atosiban TFA. Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.
    Atosiban-d5 TFA
  • HY-17573S
    Carbetocin-d7
    Carbetocin-d7 is the deuterium labeled Carbetocin (HY-17573). Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS.
    Carbetocin-d7
  • HY-175763
    Z55660043 865271-09-6
    Z55660043 is a Regulator of G protein signaling-14 (RGS14) inhibitor with an IC50 of 2.3  μM. Z55660043 selectively and non-covalently inhibits RGS14 GTPase-accelerating protein (GAP) activity without measurable cytotoxicity. Z55660043 can be used for central nervous system and metabolic disorders research.
    Z55660043
  • HY-175807
    ppGalNAc-T2-IN-1 1112431-86-3 98%
    ppGalNAc-T2-IN-1 is a polypeptide N-acetylgalactosaminyltransferase 2 (ppGalNAc-T2) inhibitor with an IC50 of 7.11 μM. ppGalNAc-T2-IN-1 is applicable for research on metabolic and neurodevelopmental disorders.
    ppGalNAc-T2-IN-1
  • HY-176062
    PPARγ modulator-3 98%
    PPARγ modulator-3 (Compound 11) is a peroxisome proliferator-activated receptor γ (PPARγ) modulator with a KD value of 186 nM. PPARγ modulator-3 is promising for research of insulin resistance (IR)-related diseases, such as type 2 diabetes mellitus (T2DM) and metabolic syndrome.
    PPARγ modulator-3
  • HY-176115
    Sphingosine (d18:1(14Z))
    Sphingosine (d18:1(14Z)) is an atypical sphingolipid that has a cis double bond at the 14-15 position. Sphingosine is a negative regulator of cell proliferation and can promote apoptosis.
    Sphingosine (d18:1(14Z))
  • HY-176127
    JX10 98%
    JX10 is a senomorphic agent. JX10 suppresses the expression of p38 MAPK and NF-κB. JX10 exhibits competent antiaging effects in C. elegans, senescent cells, and aged mice.
    JX10
  • HY-176148
    ZGL-18 3068828-64-5 98%
    ZGL-18 is an uncoupling protein 1 (UCP1)-inspired mitochondrial uncoupler. ZGL-18 activates brown adipocytes and reduces mitochondrial membrane potential.
    ZGL-18
  • HY-176196
    APOL1-IN-3 2762826-72-0 98%
    APOL1-IN-3 (Compound 1) is an APOL1 inhibitor. APOL1-IN-3 can be used in the research of kidney diseases.
    APOL1-IN-3
  • HY-176214
    PPARγ agonist 19
    PPARγ agonist 19 (Compound 5e) is a PPARγ agonist. PPARγ agonist 19 has an IC50 of 11.27 μM against COX-1 and an IC50 of 0.05 μM against COX-1. PPARγ agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956). PPARγ agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction.
    PPARγ agonist 19
  • HY-176221
    α-Glucosidase-IN-92
    α-Glucosidase-IN-92 (compound 14b) is a non-competitive inhibitor targeting α-glucosidase (IC50=64.0 μM), with better inhibitory potency than Acarbose (HY-B0089) (IC50=750 μM). α-Glucosidase-IN-92 has good oral bioavailability and can cross the blood-brain barrier. α-Glucosidase-IN-92 can delay carbohydrate hydrolysis and reduce postprandial blood glucose. α-Glucosidase-IN-92 can be used in anti-glycemic research for type 2 diabetes.
    α-Glucosidase-IN-92
  • HY-176236
    Lipophagy inducer 1 98%
    Lipophagy inducer 1 is a lipophagy inducer. Lipophagy inducer 1 has activity of reducing lipid droplet accumulation and rescuing cell death. Lipophagy inducer 1 exerts its effects by activating lipophagy, increasing steady-state autophagosome and regulating the LXR signaling pathway. Lipophagy inducer 1 can be used in the study of diabetic nephropathy (DKD) and other diseases related to lipid metabolism disorders.
    Lipophagy inducer 1
  • HY-176238
    CX116 98%
    CX116 is an orally active anti-inflammatory agent. CX116 exerts its effects by inhibiting the inflammatory response, reducing oxidative stress, protecting mitochondrial function, and counteracting apoptosis. CX116 bears acceptable toxicity, and can significantly protect renal tissue from Cisplatin (HY-17394)-induced damage. CX116 can be used for the study of Cisplatin-induced acute kidney injury (cis-AKI).
    CX116
  • HY-17623S
    Tegoprazan-d6 98%
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases.
    Tegoprazan-d6
  • HY-176274
    FASN/SCD-IN-1 3063509-61-2 98%
    FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH.
    FASN/SCD-IN-1
  • HY-176431
    TLCD1-IN-1 98%
    TLCD1-IN-1 (compound MB-4A) is a covalent TLCD1 inhibitor. TLCD1-IN-1 stereoselectively engages and inhibits TLCD1 in HepG2 cells.
    TLCD1-IN-1
  • HY-176493
    GLP-1R agonist 33 2428641-93-2
    GLP-1R agonist 33 (Compound 224) is a GLP-1 receptor agonist. GLP-1R agonist 33 has the potential to study diabetes, obesity and non-alcoholic fatty liver disease (NAFLD).
    GLP-1R agonist 33
  • HY-176497
    GW273297X 1713317-28-2 98%
    GW273297X is a selective CYP27A1 inhibitor. GW273297X blocks 27-hydroxycholesterol biosynthesis and sterol product formation in human macrophages. GW273297X reduces cancer cells colonization by inhibiting pro-metastatic effects of 27-hydroxycholesterol. GW273297X can be used for the researches of cancer and metabolic disease, such as breast cancer.
    GW273297X
  • HY-176554
    sEH-IN-21 3084814-46-7 98%
    sEH-IN-21 is an orally active sEH inhibitor with IC50s of 0.1 nM for hsEH and msEH. sEH-IN-21 potently inhibits NF-κB signaling pathways. sEH-IN-21 shows a strong anti-inflammatory activity, decreases the release of IL-6 and TNF-α and maintained the integrity of the intestinal barrier. sEH-IN-21 can be used for the study of inflammatory bowel disease (IBD).
    sEH-IN-21
  • HY-176720
    NQO1 inducer 1
    NQO1 inducer 1 (Compound 20) is a potent NQO1 inducer (CD=3 μM). NQO1 inducer 1 is a promising antioxidant that can be used for the research of redox-modulating.
    NQO1 inducer 1
Cat. No. Product Name / Synonyms Application Reactivity